Cytokinetics Insider Sold Shares Worth $414,401, According to a Recent SEC Filing
Health Check: How Prudently Does Cytokinetics (NASDAQ:CYTK) Use Debt?
B.Riley Financial Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $92
B.Riley Financial analyst Mayank Mamtani maintains $Cytokinetics(CYTK.US)$ with a buy rating, and maintains the target price at $92.According to TipRanks data, the analyst has a success rate of 26.8%
Buy Rating Justified for Cytokinetics Amid Promising Clinical Data and Drug Class Expansion Potential
Jefferies Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $92
Jefferies analyst Akash Tewari maintains $Cytokinetics(CYTK.US)$ with a buy rating, and maintains the target price at $92.According to TipRanks data, the analyst has a success rate of 58.0% and a
Cytokinetics Sets Stage For Mid-Stage Study For Heart Failure Drug After Encouraging Data From Phase 1 Study